Table 2.
Treatment history at study inclusion in the first-line mCRPC treatment population
| Prior treatment, n (%) | Patients who had not received previous mCRPC treatment at baseline n = 1874 | First-line treatment with | ||
|---|---|---|---|---|
| Abiraterone n = 754 | Enzalutamide n = 227 | Docetaxel n = 602 | ||
| Orchiectomy since initial diagnosis | 123 (6.6) | 35 (4.6) | 12 (5.3) | 44 (7.3) |
| Radical prostatectomy/prostate-specific radiotherapy since initial diagnosis | ||||
| Both radical prostatectomy and prostate-specific radiotherapy | 160 (8.5) | 79 (10.5) | 18 (7.9) | 52 (8.6) |
| Radical prostatectomy only | 190 (10.1) | 89 (11.8) | 21 (9.3) | 57 (9.5) |
| Prostate-specific radiotherapy only | 399 (21.3) | 174 (23.1) | 46 (20.3) | 140 (23.3) |
| None | 1125 (60.0) | 412 (54.6) | 142 (62.6) | 353 (58.6) |
| Prior systemic anticancer therapy | ||||
| Any | 1774 (94.7) | 718 (95.2) | 213 (93.8) | 567 (94.2) |
| Endocrine therapy | 1755 (93.6) | 710 (94.2) | 211 (93.0) | 562 (93.4) |
| Antiandrogen | 1569 (83.7) | 646 (85.7) | 188 (82.8) | 506 (84.1) |
| GnRH agonist | 1280 (68.3) | 474 (62.9) | 211 (93.0) | 434 (72.1) |
| Steroids | 194 (10.4) | 76 (10.1) | 22 (9.7) | 75 (12.5) |
| GnRH antagonist | 127 (6.8) | 64 (8.5) | 9 (4.0) | 39 (6.5) |
| Estrogens and derivatives | 53 (2.8) | 28 (3.7) | 7 (3.1) | 5 (0.8) |
| Adrenal synthesis inhibitors | 14 (0.7) | 6 (0.8) | 0 (0) | 7 (1.2) |
| Other | 6 (0.3) | 0 (0) | 3 (1.3) | 2 (0.3) |
| Bone-targeted | ||||
| Any | 455 (24.3) | 163 (21.6) | 32 (14.1) | 176 (29.2) |
| Zoledronic acid | 330 (17.6) | 120 (15.9) | 20 (8.8) | 126 (20.9) |
| Denosumab | 103 (5.5) | 45 (6.0) | 10 (4.4) | 32 (5.3) |
| Other | 55 (2.9) | 9 (1.2) | 6 (2.6) | 32 (5.3) |
| Other | 28 (1.5) | 12 (1.6) | 5 (2.2) | 7 (1.2) |
GnRH gonadotropin-releasing hormone, mCRPC metastatic castration-resistant prostate cancer